BioMarin Pharmaceutical Inc. BMRN
61.43 USD +2.92 (+4.99%)
Regular-session close
61.43 0.00 0.00%
After hours · Nov 18, 5:24 PM ET
58.28 Day range 61.69
49.26 52-week range 70.98
- YTD
- +3.37%
- 1 year
- +13.42%
News
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
marketbeat.com BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive…
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $103 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.
marketbeat.com BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a…
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
defenseworld.net Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor…
defenseworld.net Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an…benzinga.com JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86 JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.
seekingalpha.com BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a…
prnewswire.com BioMarin to Participate in Upcoming Investor Conferences Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL,…benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.
benzinga.com Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.
benzinga.com HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
benzinga.com RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.
benzinga.com Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66 Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin…
marketbeat.com BioMarin Pharmaceutical Q3 Earnings Call Highlights BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus…
zacks.com BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
zacks.com BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a…
benzinga.com Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript Biomarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over…
benzinga.com BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 Est; Lowers FY2026 Sales Guidance from $3.875B-$3.925B to $3.800B-$3.900B vs $3.918B Est BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2026 Adj EPS guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 analyst estimate. Lowers FY2026 sales outlook from $3.875 billion-$3.925 billion to…
prnewswire.com BioMarin Reports Third Quarter 2026 Financial and Operating Results Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026…
defenseworld.net BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and…benzinga.com BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
prnewswire.com BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront…
prnewswire.com BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
defenseworld.net Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to its most recent filing with the SEC. The fund bought…benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
benzinga.com Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
zacks.com BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F…
